Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.4
Journals
JCDD
Special Issues
Understanding Heart Failure Management and Treatment
share announcement

Understanding Heart Failure Management and Treatment

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Acquired Cardiovascular Disease".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 21478

Special Issue Editors

Dr. Julio Núñez
*
E-Mail Website
Guest Editor
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, 46010 Valencia, Spain
Interests: heart failure; biomarkers; ischemic heart disease; renal dysfunction
* Former Guest Editor
Special Issues, Collections and Topics in MDPI journals
Dr. Enrique Santas
*
E-Mail Website
Guest Editor
Department of Cardiology, University Clinical Hospital, 46010 Valencia, Spain
Interests: heart failure; cardiac Imaging; cardiomyopathies; valvular heart disease
* Former Guest Editor
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure, the focus of this Special Issue, is a major and growing public health problem. About 26 million adults worldwide are living with heart failure. The prevalence of heart failure is approximately 1–2% of the adult population but is up to >10% among people >70 years of age. Patients with heart failure are on a downward spiral, with frequent hospitalizations and high mortality rates, accounting for a significant economic burden to healthcare systems and caregivers, and deeply affecting patient quality of life. However, research in heart failure is an exciting field, and recent years have witnessed important progresses in prevention, risk stratification, diagnosis, management, and treatment of heart failure. In this Special Issue of the Journal of Cardiovascular Development and Disease, we invite you to consider contributing with an original investigation, research paper or review article to any aspect related to heart failure management and treatment. This is an opportunity for any physician or researcher involved in heart failure to contribute to this exciting field and to the remarkable journey of advances in its management and therapeutics.

This Special Issue will provide a platform for the presentation of recent advances in knowledge on form–function relationships in the developing and mature cardiovascular system coming from diverse scientific disciplines.

Dr. Julio Núñez
Dr. Enrique Santas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure 
  • biomarkers 
  • cardiac imaging 
  • therapeutics 
  • devices 
  • risk stratification 
  • prognosis

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 536 KiB  
Article
Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy
by Carles Díez-López, Joel Salazar-Mendiguchía, Elena García-Romero, Lara Fuentes, Josep Lupón, Antoni Bayés-Genis, Nicolás Manito, Marta de Antonio, Pedro Moliner, Elisabet Zamora, Pablo Catalá-Ruiz, Miguel Caínzos-Achirica, Josep Comín-Colet and José González-Costello
J. Cardiovasc. Dev. Dis. 2022, 9(1), 20; https://doi.org/10.3390/jcdd9010020 - 11 Jan 2022
Cited by 3 | Viewed by 3813
Abstract
Aims: Non-ischaemic dilated cardiomyopathy (NIDCM) is characterized by left ventricular (LV) chamber enlargement and systolic dysfunction in the absence of coronary artery disease. Left ventricular reverse remodelling (LVRR) is the ability of a dilated ventricle to restore its normal size, shape and function. [...] Read more.
Aims: Non-ischaemic dilated cardiomyopathy (NIDCM) is characterized by left ventricular (LV) chamber enlargement and systolic dysfunction in the absence of coronary artery disease. Left ventricular reverse remodelling (LVRR) is the ability of a dilated ventricle to restore its normal size, shape and function. We sought to determine the frequency, clinical predictors and prognostic implications of LVRR, in a cohort of heart failure (HF) patients with NIDCM. Methods: We conducted a multicentre observational, retrospective cohort study of patients with NIDCM, with prospective serial echocardiography evaluations. LVRR was defined as an increase of ≥15% in left ventricular ejection fraction (LVEF) or as a LVEF increase ≥ 10% plus reduction of LV end-systolic diameter index ≥ 20%. We used multivariable logistic regression analyses to identify the baseline clinical predictors of LVRR and evaluate the prognostic impact of LVRR. Results: LVRR was achieved in 42.5% of 527 patients with NIDCM during the first year of follow-up (median LVEF 49%, median change +22%), Alcoholic aetiology, HF duration, baseline LVEF and the absence of LBBB (plus NT-proBNP levels when in the model), were the strongest predictors of LVRR. During a median follow-up of 47 months, 134 patients died (25.4%) and 7 patients (1.3%) received a heart transplant. Patients with LVRR presented better outcomes, regardless of other clinical conditions. Conclusions: In patients with NIDCM, LVRR was frequent and was associated with improved prognosis. Major clinical predictors of LVRR were alcoholic cardiomyopathy, absence of LBBB, shorter HF duration, and lower baseline LVEF and NT-proBNP levels. Our study advocates for clinical phenotyping of non-ischaemic dilated cardiomyopathy and intense gold-standard treatment optimization of patients according to current guidelines and recommendations in specialized HF units. Full article
(This article belongs to the Special Issue Understanding Heart Failure Management and Treatment)
►▼ Show Figures

Figure 1

8 pages, 1151 KiB  
Article
Optimal Heart Rate and Prognosis in Patients with Cardiac Amyloidosis
by Toshihide Izumida, Teruhiko Imamura, Makiko Nakamura and Koichiro Kinugawa
J. Cardiovasc. Dev. Dis. 2021, 8(12), 182; https://doi.org/10.3390/jcdd8120182 - 12 Dec 2021
Cited by 2 | Viewed by 2473
Abstract
Background: Optimal heart rate (HR) that associates with higher cardiac output and greater clinical outcomes in patients with cardiac amyloidosis remains unknown. Methods: Consecutive patients with sinus rhythm who were diagnosed with cardiac amyloidosis at our institute between February 2015 and February 2021 [...] Read more.
Background: Optimal heart rate (HR) that associates with higher cardiac output and greater clinical outcomes in patients with cardiac amyloidosis remains unknown. Methods: Consecutive patients with sinus rhythm who were diagnosed with cardiac amyloidosis at our institute between February 2015 and February 2021 were retrospectively included. Ideal HR, at which E-wave and A-wave stand adjacent without any overlaps in the trans-mitral flow echocardiography, was calculated by the formula: 86.8−0.08 × deceleration time (msec). The association between optimal HR and cardiac death or heart failure readmission was investigated. Results: Ten patients (median 74 years old, 8 men) were included. On median, actual HR was 64 bpm and ideal HR was 69 bpm. An incidence rate of the primary endpoint in the sub-optimal HR group tended to be higher than optimal HR group: one of the four patients in optimal HR group had events (25%); two of the two patients in higher HR group had events (100%); two of the four patients in lower HR group had events (50%). Conclusions: The optimal HR was associated with greater clinical outcomes in patients with cardiac amyloidosis. The clinical impact of aggressive HR optimization in this cohort remains the next concern. Full article
(This article belongs to the Special Issue Understanding Heart Failure Management and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

28 pages, 2622 KiB  
Review
A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches
by Vivek Sarohi, Shriya Srivastava and Trayambak Basak
J. Cardiovasc. Dev. Dis. 2022, 9(6), 174; https://doi.org/10.3390/jcdd9060174 - 1 Jun 2022
Cited by 8 | Viewed by 4210
Abstract
Dilated cardiomyopathy (DCM) remains an enigmatic cardiovascular disease (CVD) condition characterized by contractile dysfunction of the myocardium due to dilation of the ventricles. DCM is one of the major forms of CVD contributing to heart failure. Dilation of the left or both ventricles [...] Read more.
Dilated cardiomyopathy (DCM) remains an enigmatic cardiovascular disease (CVD) condition characterized by contractile dysfunction of the myocardium due to dilation of the ventricles. DCM is one of the major forms of CVD contributing to heart failure. Dilation of the left or both ventricles with systolic dysfunction, not explained by known causes, is a hallmark of DCM. Progression of DCM leads to heart failure. Genetic and various other factors greatly contribute to the development of DCM, but the etiology has still remained elusive in a large number of cases. A significant number of studies have been carried out to identify the genetic causes of DCM. These candidate-gene studies revealed that mutations in the genes of the fibrous, cytoskeletal, and sarcomeric proteins of cardiomyocytes result in the development of DCM. However, a significant proportion of DCM patients are idiopathic in nature. In this review, we holistically described the symptoms, causes (in adults and newborns), genetic basis, and mechanistic progression of DCM. Further, we also summarized the state-of-the-art diagnosis, available biomarkers, treatments, and ongoing clinical trials of potential drug regimens. DCM-mediated heart failure is on the rise worldwide including in India. The discovery of biomarkers with a better prognostic value is the need of the hour for better management of DCM-mediated heart failure patients. With the advent of next-generation omics-based technologies, it is now possible to probe systems-level alterations in DCM patients pertaining to the identification of novel proteomic and lipidomic biomarkers. Here, we also highlight the onset of a systems-level study in Indian DCM patients by applying state-of-the-art mass-spectrometry-based “clinical proteomics” and “clinical lipidomics”. Full article
(This article belongs to the Special Issue Understanding Heart Failure Management and Treatment)
►▼ Show Figures

Figure 1

17 pages, 1079 KiB  
Review
Cognitive Impairment in Acute Heart Failure: Narrative Review
by Ioannis Ventoulis, Angelos Arfaras-Melainis, John Parissis and Eftihia Polyzogopoulou
J. Cardiovasc. Dev. Dis. 2021, 8(12), 184; https://doi.org/10.3390/jcdd8120184 - 14 Dec 2021
Cited by 6 | Viewed by 2945
Abstract
Cognitive impairment (CI) represents a common but often veiled comorbidity in patients with acute heart failure (AHF) that deserves more clinical attention. In the AHF setting, it manifests as varying degrees of deficits in one or more cognitive domains across a wide spectrum [...] Read more.
Cognitive impairment (CI) represents a common but often veiled comorbidity in patients with acute heart failure (AHF) that deserves more clinical attention. In the AHF setting, it manifests as varying degrees of deficits in one or more cognitive domains across a wide spectrum ranging from mild CI to severe global neurocognitive disorder. On the basis of the significant negative implications of CI on quality of life and its overwhelming association with poor outcomes, there is a compelling need for establishment of detailed consensus guidelines on cognitive screening methods to be systematically implemented in the population of patients with heart failure (HF). Since limited attention has been drawn exclusively on the field of CI in AHF thus far, the present narrative review aims to shed further light on the topic. The underlying pathophysiological mechanisms of CI in AHF remain poorly understood and seem to be multifactorial. Different pathophysiological pathways may come into play, depending on the clinical phenotype of AHF. There is some evidence that cognitive decline closely follows the perturbations incurred across the long-term disease trajectory of HF, both along the time course of stable chronic HF as well as during episodes of HF exacerbation. CI in AHF remains a rather under recognized scientific field that poses many challenges, since there are still many unresolved issues regarding cognitive changes in patients hospitalized with AHF that need to be thoroughly addressed. Full article
(This article belongs to the Special Issue Understanding Heart Failure Management and Treatment)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

6 pages, 1288 KiB  
Case Report
Successful Management of Pheochromocytoma Crisis with Cardiogenic Shock by Percutaneous Left Ventricular Assist Device
by Makiko Nakamura, Teruhiko Imamura, Takuya Fukui, Akira Oshima, Hiroshi Ueno and Koichiro Kinugawa
J. Cardiovasc. Dev. Dis. 2022, 9(3), 71; https://doi.org/10.3390/jcdd9030071 - 27 Feb 2022
Cited by 1 | Viewed by 1999
Abstract
Therapeutic strategy utilizing mechanical circulatory supports in patients with pheochromocytoma-related cardiogenic shock remains unestablished. We had a 51-year-old man with acute decompensated heart failure due to pheochromocytoma crisis. He received a percutaneous left ventricular assist device-supported alpha-blocker and intensive fluid infusion therapy, which [...] Read more.
Therapeutic strategy utilizing mechanical circulatory supports in patients with pheochromocytoma-related cardiogenic shock remains unestablished. We had a 51-year-old man with acute decompensated heart failure due to pheochromocytoma crisis. He received a percutaneous left ventricular assist device-supported alpha-blocker and intensive fluid infusion therapy, which ameliorated impaired end-organ dysfunction, maintaining hemodynamics and achieving cardiac recovery, followed by the successfully scheduled adrenalectomy. Early suspicion of pheochromocytoma and Impella-supported disease-specific medical management might be a promising bridge to surgery strategy. Full article
(This article belongs to the Special Issue Understanding Heart Failure Management and Treatment)
►▼ Show Figures

Figure 1

7 pages, 4277 KiB  
Case Report
A Case of T/NK-Cell Post-Transplantation Lymphoproliferative Disease 7 Years after Heart Transplantation
by Makiko Nakamura, Teruhiko Imamura, Kohji Takagi, Masakazu Hori, Shinichi Tanaka, Joji Imura and Koichiro Kinugawa
J. Cardiovasc. Dev. Dis. 2022, 9(2), 38; https://doi.org/10.3390/jcdd9020038 - 24 Jan 2022
Cited by 1 | Viewed by 2150
Abstract
Post-transplant lymphoproliferative diseases (PTLD) are potentially fatal complications after cardiac transplantation. Most cases are Epstein–Barr virus (EBV)-related B-cell tumors, and reduction of immunosuppression treatment as well as the use of rituximab in combination with other chemotherapy are effective. However, patients with T/NK-cell PTLD [...] Read more.
Post-transplant lymphoproliferative diseases (PTLD) are potentially fatal complications after cardiac transplantation. Most cases are Epstein–Barr virus (EBV)-related B-cell tumors, and reduction of immunosuppression treatment as well as the use of rituximab in combination with other chemotherapy are effective. However, patients with T/NK-cell PTLD post-cardiac transplantation are rarely reported. We had a patient with a fever that lasted for three weeks, with lung infiltrations and hepatosplenomegaly, who had EBV-associated hemophagocytosis 7 years after heart transplantation and was eventually diagnosed with T/NK-cell PTLD by autopsy. Although rare diseases, regular monitoring of EBV-DNA levels might be crucial for early diagnosis and treatment of PTLD. Full article
(This article belongs to the Special Issue Understanding Heart Failure Management and Treatment)
►▼ Show Figures

Graphical abstract

4 pages, 7994 KiB  
Case Report
Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
by Teruhiko Imamura, Yohei Ueno and Koichiro Kinugawa
J. Cardiovasc. Dev. Dis. 2021, 8(12), 189; https://doi.org/10.3390/jcdd8120189 - 17 Dec 2021
Cited by 3 | Viewed by 2819
Abstract
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor is a recently introduced oral agent to treat renal anemia, but its clinical implications on renal functioning in patients with heart failure remains unknown. We studied an 81-year-old man with heart failure with mildly reduced ejection fraction, [...] Read more.
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor is a recently introduced oral agent to treat renal anemia, but its clinical implications on renal functioning in patients with heart failure remains unknown. We studied an 81-year-old man with heart failure with mildly reduced ejection fraction, chronic kidney disease, and renal anemia. The seven-month HIF-PH inhibitor daprodustat treatment improved the hemoglobin level from 7.4 g/dL to 11.8 g/dL and estimated glomerular filtration ratio from 24 mL/min/1.73 m2 to 35 mL/min/1.73 m2 without any complications, including thromboembolic events. HIF-PH inhibitor might be a promising therapeutic tool to improve renal anemia and renal function in patients with heart failure, although large-scale studies are warranted to validate our findings. Full article
(This article belongs to the Special Issue Understanding Heart Failure Management and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop